Implementation of near-universal hydroxyurea uptake among children with sickle cell anemia: A single-center experience.
Karkoska, K; Todd, K; Niss, O; Clapp, K; Fenchel, L; Kalfa, TA; Malik, P; Quinn, CT; Ware, RE; McGann, PT.
Pediatric Blood and Cancer.
2021;
68.
Hydroyxurea improves cerebral oxygen saturation in children with sickle cell anemia.
Karkoska, K; Quinn, CT; Niss, O; Pfeiffer, A; Dong, M; Vinks, AA; McGann, PT.
American Journal of Hematology.
2021;
96:538-544.
Congenital dyserythropoietic anemia type I: First report from the Congenital Dyserythropoietic Anemia Registry of North America (CDAR).
Niss, O; Lorsbach, RB; Berger, M; Chonat, S; McLemore, M; Buchbinder, D; McCavit, T; Shaffer, LG; Simpson, J; Schwartz, JH; et al.
Blood Cells, Molecules, and Diseases.
2021;
87.
Left atrial dysfunction in sickle cell anemia is associated with diffuse myocardial fibrosis, increased right ventricular pressure and reduced exercise capacity.
Alsaied, T; Niss, O; Tretter, JT; Powell, AW; Chin, C; Fleck, RJ; Cnota, JF; Malik, P; Quinn, CT; Nagueh, SM; et al.
Scientific Reports.
2020;
10.
Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia.
Meier, ER; Creary, SE; Heeney, MM; Dong, M; Appiah-Kubi, AO; Nelson, SC; Niss, O; Piccone, C; Quarmyne, MO; Quinn, CT; et al.
Trials.
2020;
21.
Reversible Myelofibrosis in Pediatric Renal Osteodystrophy.
Sabulski, A; Hughley, E; Nehus, EJ; Grier, DD; Niss, O.
Journal of Pediatrics.
2020.
Lymphopenia in adults after the Fontan operation: prevalence and associations.
Alsaied, T; Possner, M; Brown, N; Almeneisi, H; Szugye, C; Trout, AT; Niss, O; Palermo, JJ; Zafar, F; Dillman, JR; et al.
Cardiology in the Young.
2020;
30:641-648.
Progression of albuminuria in patients with sickle cell anemia: a multicenter, longitudinal study.
Niss, O; Lane, A; Asnani, MR; Yee, ME; Raj, A; Creary, S; Fitzhugh, C; Bodas, P; Saraf, SL; Sarnaik, S; et al.
Blood Advances.
2020;
4:1501-1511.
Congenital Dyserythropoietic Anemia Type I Due to Biallelic CDAN1 mutations: Report from the Congenital Dyserythropoietic Anemia Registry (CDAR).
Niss, O; Lorsbach, RB; Buchbinder, DK; Chonat, S; McLemore, ML; McCavit, T; Schwartz, JH; Meznarich, J; Seu, K; Zhang, W; et al.
Blood.
2019;
134:3521-3521.
Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia.
McGann, PT; Niss, O; Dong, M; Marahatta, A; Howard, TA; Mizuno, T; Lane, A; Kalfa, TA; Malik, P; Quinn, CT; et al.
American Journal of Hematology.
2019;
94:871-879.